drugset / Trial / NCT06027073

Biologics and Sublingual Immunotherapy

NCT06027073

RandomizedParallel-groupOpen-labelTreatment

Summary

Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

Timeline

Start
2024-05-01
Primary completion
2026-10-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody

Indications